drugset / Trial / NCT05545319
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
Timeline
- Start
- 2022-12-13
- Primary completion
- 2023-09-21
- Completion
- 2024-01-06
Outcome
Outcome not reported
Stopped: “Termination due to challenges related to the operational feasibility of the study, taking into account the current epidemiology and declining hospitalization rates for severe COVID-19.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nirmatrelvir | Small molecule | 150 mg | Oral |
| Subject | Nirmatrelvir | Small molecule | 300 mg | Oral |
| Background | Ritonavir | Other / unclassified | 100 mg | Oral |